Plasmodium falciparum

• 

  Subject Areas on Research

  • 1,2,4-Trioxanes as potential antimalarial agents. 
  • A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment. 
  • A bifunctional dihydrofolate synthetase--folylpolyglutamate synthetase in Plasmodium falciparum identified by functional complementation in yeast and bacteria. 
  • A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan. 
  • A cross-sectional survey of Plasmodium falciparum pfcrt mutant haplotypes in the Democratic Republic of Congo. 
  • A deep sequencing approach to estimate Plasmodium falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity. 
  • A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDa. 
  • A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. 
  • A microarray platform and novel SNP calling algorithm to evaluate Plasmodium falciparum field samples of low DNA quantity. 
  • A molecular marker for chloroquine-resistant falciparum malaria. 
  • A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples. 
  • A novel method for extracting nucleic acids from dried blood spots for ultrasensitive detection of low-density Plasmodium falciparum and Plasmodium vivax infections. 
  • A set of microsatellite markers to differentiate Plasmodium falciparum progeny of four genetic crosses. 
  • Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. 
  • Adaptive evolution and fixation of drug-resistant Plasmodium falciparum genotypes in pregnancy-associated malaria: 9-year results from the QuEERPAM study. 
  • Amodiaquine and sulfadoxine-pyrimethamine as treatment for chloroquine-resistant Plasmodium falciparum in Rwanda. 
  • An ultrasensitive reverse transcription polymerase chain reaction assay to detect asymptomatic low-density Plasmodium falciparum and Plasmodium vivax infections in small volume blood samples. 
  • Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. 
  • Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. 
  • Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure. 
  • Antibody Profiling by Proteome Microarray with Multiplex Isotype Detection Reveals Overlap between Human and Aotus nancymaae Controlled Malaria Infections. 
  • Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. 
  • Antigen-specific B memory cell responses to Plasmodium falciparum malaria antigens and Schistosoma haematobium antigens in co-infected Malian children. 
  • Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. 
  • Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. 
  • Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot. 
  • Artemisinin resistance in Myanmar. 
  • Artemisinin resistance in Plasmodium falciparum malaria. 
  • Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model. 
  • Artemisinin-Resistant Plasmodium falciparum in Africa. 
  • Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. 
  • Assessing the safety and efficacy of a test-based, targeted donor screening strategy to minimize transfusion transmitted malaria. 
  • Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. 
  • Association of HLA alleles with Plasmodium falciparum severity in Malian children. 
  • Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. 
  • Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. 
  • Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. 
  • Asymptomatic Plasmodium falciparum malaria in pregnant women in the Chittagong Hill Districts of Bangladesh. 
  • Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. 
  • Automated Detection of P. falciparum Using Machine Learning Algorithms with Quantitative Phase Images of Unstained Cells. 
  • Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. 
  • Cases from the Osler Medical Service at Johns Hopkins University. 
  • Cell-mediated immune responses to vaccine peptides derived from the circumsporozoite protein of Plasmodium falciparum. 
  • Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. 
  • Changes in the levels of chemokines and cytokines in the placentas of women with Plasmodium falciparum malaria. 
  • Characterization of Plasmodium liver stage inhibition by halofuginone. 
  • Characterization of a UBC13 kinase in Plasmodium falciparum. 
  • Chloroquine resistance of Plasmodium falciparum is associated with severity of disease in Nigerian children. 
  • Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. 
  • Chloroquine-resistant malaria. 
  • Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. 
  • Community pyrimethamine-sulfadoxine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. 
  • Complexity of the msp2 locus and the severity of childhood malaria, in south-western Nigeria. 
  • Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum. 
  • Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. 
  • Decreased circulating macrophage migration inhibitory factor (MIF) protein and blood mononuclear cell MIF transcripts in children with Plasmodium falciparum malaria. 
  • Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. 
  • Designing malaria vaccines to circumvent antigen variability. 
  • Detection of Plasmodium falciparum in pregnancy by laser desorption mass spectrometry. 
  • Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. 
  • Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. 
  • Developmental allometry and paediatric malaria. 
  • Differential recognition of terminal extracellular Plasmodium falciparum VAR2CSA domains by sera from multigravid, malaria-exposed Malian women. 
  • Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. 
  • Dihydroquinazolinone inhibitors of proliferation of blood and liver stage malaria parasites. 
  • Discovery of Dual-Stage Malaria Inhibitors with New Targets. 
  • Discovery of novel targets of quinoline drugs in the human purine binding proteome. 
  • Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. 
  • Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. 
  • Efficacy of chloroquine on Plasmodium falciparum transmitted at Amani, eastern Usambara Mountains, north-east Tanzania: an area where malaria has recently become endemic. 
  • Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia. 
  • Erythrocyte CR1 expression level does not correlate with a HindIII restriction fragment length polymorphism in Africans; implications for studies on malaria susceptibility. 
  • Erythrocyte invasion profiles are associated with a common invasion ligand polymorphism in Senegalese isolates of Plasmodium falciparum. 
  • Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance. 
  • Expression of complement and toll-like receptor pathway genes is associated with malaria severity in Mali: a pilot case control study. 
  • Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors. 
  • Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. 
  • External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance. 
  • Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. 
  • Fever in patients with mixed-species malaria. 
  • Genetic Evidence of Importation of Drug-Resistant Plasmodium falciparum to Guatemala from the Democratic Republic of the Congo. 
  • Genetic architecture of artemisinin-resistant Plasmodium falciparum. 
  • Genetic diversity of the msp-1 locus and symptomatic malaria in south-west Nigeria. 
  • Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. 
  • Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. 
  • Genomic epidemiology of artemisinin resistant malaria. 
  • Genomic structure and diversity of Plasmodium falciparum in Southeast Asia reveal recent parasite migration patterns. 
  • HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. 
  • Hemoglobin E and Glucose-6-Phosphate Dehydrogenase Deficiency and Plasmodium falciparum Malaria in the Chittagong Hill Districts of Bangladesh. 
  • Hemoglobin consumption by P. falciparum in individual erythrocytes imaged via quantitative phase spectroscopy. 
  • Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. 
  • High levels of Plasmodium falciparum rosetting in all clinical forms of severe malaria in African children. 
  • Higher production of peripheral blood macrophage migration inhibitory factor in healthy children with a history of mild malaria relative to children with a history of severe malaria. 
  • Host iron status and iron supplementation mediate susceptibility to erythrocytic stage Plasmodium falciparum. 
  • Hyperendemic malaria transmission in areas of occupation-related travel in the Peruvian Amazon. 
  • Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. 
  • Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity. 
  • Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. 
  • Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A. 
  • Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 
  • Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. 
  • Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. 
  • Impact of intermittent screening and treatment for malaria among school children in Kenya: a cluster randomised trial. 
  • Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. 
  • Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. 
  • Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. 
  • In vivo and in vitro susceptibility to chloroquine of Plasmodium falciparum in Kinshasa and Mbuji-Mayi, Zaire. 
  • Increased Susceptibility to Plasmodium falciparum in Infants is associated with Low, not High, Placental Malaria Parasitemia. 
  • Increased prevalence of dhfr and dhps mutants at delivery in Malawian pregnant women receiving intermittent preventive treatment for malaria. 
  • Increased risk of low birth weight in women with placental malaria associated with P. falciparum VAR2CSA clade. 
  • Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. 
  • Independent lineages of highly sulfadoxine-resistant Plasmodium falciparum haplotypes, eastern Africa. 
  • Inhibition of endothelial activation: a new way to treat cerebral malaria? 
  • Interaction between acute diarrhoea and falciparum malaria in Nigerian children. 
  • Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania. 
  • Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. 
  • Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. 
  • Lack of an association between antibodies to Plasmodium falciparum glycosylphosphatidylinositols and malaria-associated placental changes in Cameroonian women with preterm and full-term deliveries. 
  • Lessons from malaria control to elimination: case study in Hainan and Yunnan provinces. 
  • Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. 
  • Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. 
  • Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. 
  • Longitudinal studies of Plasmodium falciparum malaria in pregnant women living in a rural Cameroonian village with high perennial transmission. 
  • Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. 
  • Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence. 
  • Malaria: Resistance nailed. 
  • Mapping hypoendemic, seasonal malaria in rural Bandarban, Bangladesh: a prospective surveillance. 
  • Mechanisms of resistance of malaria parasites to antifolates. 
  • Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum. 
  • Minimal Impact by Antenatal Subpatent Plasmodium falciparum Infections on Delivery Outcomes in Malawian Women: A Cohort Study. 
  • Molecular Epidemiology of Blood-Borne Human Parasites in a Loa loa-, Mansonella perstans-, and Plasmodium falciparum-Endemic Region of Cameroon. 
  • Molecular approaches to the spreading problem of drug resistant malaria. 
  • Molecular assays for surveillance of antifolate-resistant malaria. 
  • Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. 
  • Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. 
  • Molecular malaria epidemiology: mapping and burden estimates for the Democratic Republic of the Congo, 2007. 
  • Monitoring and deterring drug-resistant malaria in the era of combination therapy. 
  • Monitoring antimalarial drug resistance: making the most of the tools at hand. 
  • More on 'the efficacy of antifolate antimalarial combinations in Africa'. 
  • Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. 
  • Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. 
  • Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. 
  • Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. 
  • Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. 
  • New var reconstruction algorithm exposes high var sequence diversity in a single geographic location in Mali. 
  • Next generation sequencing to detect variation in the Plasmodium falciparum circumsporozoite protein. 
  • Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. 
  • Ordered accumulation of mutations conferring resistance to sulfadoxine-pyrimethamine in the Plasmodium falciparum parasite. 
  • Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. 
  • Overlap Extension Barcoding for the Next Generation Sequencing and Genotyping of Plasmodium falciparum in Individual Patients in Western Kenya. 
  • Parasite prevalence: a static measure of dynamic infections. 
  • Parasitologic and clinical efficacy of 25 and 50 mg/kg of chloroquine for treatment of Plasmodium falciparum malaria in Rwandan children. 
  • Patchy ischemic retinal whitening. 
  • Pathologic changes associated with fatal Plasmodium falciparum infection in the Bolivian squirrel monkey (Saimiri sciureus boliviensis). 
  • Permethrin-impregnated curtains and bed-nets prevent malaria in western Kenya. 
  • Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi. 
  • Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. 
  • Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. 
  • Plasma Plasmodium falciparum histidine-rich protein-2 concentrations are associated with malaria severity and mortality in Tanzanian children. 
  • Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. 
  • Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype. 
  • Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. 
  • Plasmodium falciparum malaria: band 3 as a possible receptor during invasion of human erythrocytes. 
  • Plasmodium falciparum sulfadoxine resistance is geographically and genetically clustered within the DR Congo. 
  • Plasmodium falciparum, anaemia and cognitive and educational performance among school children in an area of moderate malaria transmission: baseline results of a cluster randomized trial on the coast of Kenya. 
  • Plasmodium falciparum-infected erythrocytes adhere both in the intervillous space and on the villous surface of human placenta by binding to the low-sulfated chondroitin sulfate proteoglycan receptor. 
  • Platelet-mediated clumping of Plasmodium falciparum infected erythrocytes is associated with high parasitemia but not severe clinical manifestations of malaria in African children. 
  • Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum isolates from Venezuela. 
  • Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. 
  • Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali. 
  • Polysome profiling of the malaria parasite Plasmodium falciparum. 
  • Pooled deep sequencing of Plasmodium falciparum isolates: an efficient and scalable tool to quantify prevailing malaria drug-resistance genotypes. 
  • Potentiation of cell-mediated immune responses directed against P. falciparum sporozoite peptide vaccine by immunomodulators. 
  • Prevalence of Clinical and Subclinical Plasmodium falciparum and Plasmodium vivax Malaria in Two Remote Rural Communities on the Myanmar-China Border. 
  • Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. 
  • Proteome-wide analysis reveals widespread lysine acetylation of major protein complexes in the malaria parasite. 
  • Providing lipid-based nutrient supplement during pregnancy does not reduce the risk of maternal P falciparum parasitaemia and reproductive tract infections: a randomised controlled trial. 
  • Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. 
  • Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. 
  • Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? 
  • Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens. 
  • Quantification of Plasmodium falciparum histidine-rich protein-2 in cerebrospinal spinal fluid from cerebral malaria patients. 
  • Quantification of the burden and consequences of pregnancy-associated malaria in the Democratic Republic of the Congo. 
  • Rapid Diagnostic Test Performance Assessed Using Latent Class Analysis for the Diagnosis of Plasmodium falciparum Placental Malaria. 
  • Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. 
  • Reduced T regulatory cell response during acute Plasmodium falciparum infection in Malian children co-infected with Schistosoma haematobium. 
  • Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. 
  • Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. 
  • Reply to Harrington et al. 
  • Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. 
  • Return of chloroquine antimalarial efficacy in Malawi. 
  • Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. 
  • Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. 
  • Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. 
  • Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes. 
  • Sensitive DNA detection and SNP discrimination using ultrabright SERS nanorattles and magnetic beads for malaria diagnostics. 
  • Seroreactivity to Plasmodium falciparum erythrocyte membrane protein 1 intracellular domain in malaria-exposed children and adults. 
  • Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria. 
  • Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. 
  • Sexual reproduction and the evolution of microbial pathogens. 
  • Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using high-throughput genotyping methods. 
  • Single-Cell Analysis Reveals Distinct Gene Expression and Heterogeneity in Male and Female Plasmodium falciparum Gametocytes. 
  • Spatio-Temporal Dynamics of Asymptomatic Malaria: Bridging the Gap Between Annual Malaria Resurgences in a Sahelian Environment. 
  • Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali. 
  • Spread of artemisinin resistance in Plasmodium falciparum malaria. 
  • Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine. 
  • Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. 
  • Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. 
  • Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. 
  • Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. 
  • Suppression of prostaglandin E2 by malaria parasite products and antipyretics promotes overproduction of tumor necrosis factor-alpha: association with the pathogenesis of childhood malarial anemia. 
  • Systematic comparison of two methods to measure parasite density from malaria blood smears. 
  • The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women. 
  • The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. 
  • The diagnosis of Plasmodium falciparum infection using a new antigen detection system. 
  • The evolution of drug-resistant malaria. 
  • The geography of malaria genetics in the Democratic Republic of Congo: A complex and fragmented landscape. 
  • The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. 
  • The practice of jhum cultivation and its relationship to Plasmodium falciparum infection in the Chittagong Hill Districts of Bangladesh. 
  • Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. 
  • Trans-kingdom small RNA transfer during host-pathogen interactions: The case of P. falciparum and erythrocytes. 
  • Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. 
  • Ultrastructural localization of erythrocyte cytoskeletal and integral membrane proteins in Plasmodium falciparum-infected erythrocytes. 
  • Unidirectional dominance of cytoplasmic inheritance in two genetic crosses of Plasmodium falciparum. 
  • Use of area under the curve to characterize transmission potential after antimalarial treatment. 
  • Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples. 
  • Using context to improve protein domain identification. 
  • Vaccine-Resistant Malaria. 
  • Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications. 
  • Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. 
  • [In vitro cultivation of fields isolates of Plasmodium falciparum in Mali]. 
  • [LMP-420, a new therapeutic approach for cerebral malaria?]. 
• 

  Keywords of People

  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • O'Meara, Wendy P, Associate Professor in Medicine, Medicine, Infectious Diseases